Guggenheim Capital LLC Sells 751 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Guggenheim Capital LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 37,613 shares of the biopharmaceutical company's stock after selling 751 shares during the quarter. Guggenheim Capital LLC's holdings in Regeneron Pharmaceuticals were worth $26,793,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $6,364,000. Morse Asset Management Inc boosted its stake in Regeneron Pharmaceuticals by 0.9% in the 3rd quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company's stock valued at $5,053,000 after purchasing an additional 43 shares during the period. Anchor Investment Management LLC grew its holdings in Regeneron Pharmaceuticals by 212.0% in the 3rd quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company's stock valued at $902,000 after buying an additional 583 shares in the last quarter. Sculati Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals by 1.9% in the 3rd quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company's stock valued at $1,970,000 after buying an additional 38 shares in the last quarter. Finally, Pine Valley Investments Ltd Liability Co increased its position in Regeneron Pharmaceuticals by 19.0% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company's stock worth $5,575,000 after buying an additional 848 shares during the period. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Bernstein Bank decreased their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, Citigroup lowered their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $963.56.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $13.88 during midday trading on Friday, reaching $563.16. 827,663 shares of the stock were exchanged, compared to its average volume of 713,729. Regeneron Pharmaceuticals, Inc. has a 52 week low of $525.99 and a 52 week high of $1,211.20. The company has a fifty day moving average price of $645.94 and a 200 day moving average price of $738.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $61.57 billion, a PE ratio of 14.71, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business posted $11.86 earnings per share. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.63%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.